UGT1A1*6/*28 polymorphisms could predict irinotecan-induced severe neutropenia not diarrhea in Chinese colorectal cancer patients

Medical Oncology

Volumn 30, Issue 3, 2013, Pages

  Gao, Jing ^a   Zhou, Jun ^a   Li, Yanyan ^a   Lu, Ming ^a   Jia, Ru ^a   Shen, Lin ^a  

^a PEKING UNIVERSITY   (China)

Author keywords

Diarrhea; Irinotecan; Neutropenia; Polymorphism; UGT1A1

Indexed keywords

CAPECITABINE; CETUXIMAB; GENOMIC DNA; GLUCURONOSYLTRANSFERASE 1A1; IRINOTECAN; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; GLUCURONOSYLTRANSFERASE; UGT1A1 ENZYME; DRUG DERIVATIVE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CHINESE; COLORECTAL CANCER; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DRUG SAFETY; FEMALE; GENE; GENE SEQUENCE; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NEUTROPENIA; OUTCOME ASSESSMENT; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; TREATMENT RESPONSE; UGT1A1 GENE; WESTERN HEMISPHERE; YOUNG ADULT; ADVERSE DRUG REACTION; ANALOGS AND DERIVATIVES; ASIAN CONTINENTAL ANCESTRY GROUP; CHEMICALLY INDUCED; COLORECTAL NEOPLASMS; GENETIC POLYMORPHISM; GENETICS; RETROSPECTIVE STUDY; ASIAN; CHEMICALLY INDUCED DISORDER; COLORECTAL TUMOR;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; ASIAN CONTINENTAL ANCESTRY GROUP; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DIARRHEA; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; GENOTYPE; GLUCURONOSYLTRANSFERASE; HUMANS; NEUTROPENIA; POLYMORPHISM, GENETIC; RETROSPECTIVE STUDIES;

EID: 84877737684     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-013-0604-x     Document Type: Article

References (29)

1. Bai H, Mao L, Wang HS, et al. Epidermal growth factor receptor mutations in plasma DNA samples predict tumor response in Chinese patients with stages IIIB to IV non-small-cell lung cancer. J Clin Oncol. 2009;27:2653-9.
2. Andreetta C, Puppin C, Minisini A, et al. Thymidine phosphorylase expression and benefit from capecitabine in patients with advanced breast cancer. Ann Oncol. 2009;20:265-71.
3. Pullarkat ST, Stoehlmacher J, Ghaderi V, et al. Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy. Pharmacogenomics J. 2001;1:65-70.
4. Tournigand C, André T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol. 2004;22:229-37.
5. Ohyanagi F, Horiike A, Okano Y, et al. Phase II trial of gemcitabine and irinotecan in previously treated patients with small-cell lung cancer. Cancer Chemother Pharmacol. 2008;61: 503-8.
6. Yamamoto K, Kokawa K, Umesaki N, et al. Phase I study of combination chemotherapy with irinotecan hydrochloride and nedaplatin for cervical squamous cell carcinoma: japanese gynecologic oncology group study. Oncol Rep. 2009;21:1005-9.
7. Takakura S, Takano M, Takahashi F, et al. Randomized phase II trial of paclitaxel plus carboplatin therapy versus irinotecan plus cisplatin therapy as first-line chemotherapy for clear cell adenocarcinoma of the ovary: a JGOG study. Int J Gynecol Cancer. 2010;20:240-7.
8. Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan study group. N Engl J Med. 2000;343:905-14.
9. Ando Y, Saka H, Ando M, et al. Polymorphisms of UDP- glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res. 2000;60:6921-6.
10. Desai AA, Innocenti F, Ratain MJ. Pharmacogenomics: road to anticancer therapeutics nirvana? Oncogene. 2003;22:6621-8.
11. Martinez-Balibrea E, Abad A, Martínez-Cardús A, et al. UGT1A and TYMS genetic variants predict toxicity and response of colorectal cancer patients treated with first-line irinotecan and fluorouracil combination therapy. Br J Cancer. 2010;103:581-9.
12. Liu CY, Chen PM, Chiou TJ, et al. UGT1A1*28 polymorphism predicts irinotecan-induced severe toxicities without affecting treatment outcome and survival in patients with metastatic colorectal carcinoma. Cancer. 2008;112:1932-40.
13. Ferraldeschi R, Minchell LJ, Roberts SA, et al. UGT1A1*28 genotype predicts gastrointestinal toxicity in patients treated with intermediate-dose irinotecan. Pharmacogenomics. 2009;10: 733-9.
14. Schulz C, Heinemann V, Schalhorn A, et al. UGT1A1 gene polymorphism: impact on toxicity and efficacy of irinotecanbased regimens in metastatic colorectal cancer. World J Gastroenterol. 2009;15:5058-66.
15. Glimelius B, Garmo H, Berglund A, et al. Prediction of irinotecan and 5-fluorouracil toxicity and response in patients with advanced colorectal cancer. Pharmacogenomics J. 2011;11:61-71.
16. Park SR, Kong SY, Rhee J, et al. Phase II study of a triplet regimen of S-1 combined with irinotecan and oxaliplatin in patients with metastatic gastric cancer: clinical and pharmacogenetic results. Ann Oncol. 2011;22:890-6.
17. Takano M, Kato M, Yoshikawa T, et al. Clinical significance of UDP-glucuronosyltransferase 1A1*6 for toxicities of combination chemotherapy with irinotecan and cisplatin in gynecologic cancers: a prospective multi-institutional study. Oncology. 2009;76:315-21.
18. Minami H, Sai K, Saeki M, et al. Irinotecan pharmacokinetics/ pharmacodynamics and UGT1A genetic polymorphisms in Japanese: roles of UGT1A1*6 and *28. Pharmacogenet Genomics. 2007;17:497-504.
19. Sunakawa Y, Ichikawa W, Fujita K, et al. UGT1A1*1/*28 and 1/*6 genotypes have no effects on the efficacy and toxicity of FOLFIRI in Japanese patients with advanced colorectal cancer. Cancer Chemother Pharmacol. 2011;68:279-84.
20. Shulman K, Cohen I, Barnett-Griness O, et al. Clinical implications of UGT1A1*28 genotype testing in colorectal cancer patients. Cancer. 2011;117:3156-62.
21. Jada SR, Lim R, Wong CI, et al. Role of UGT1A1*6, UGT1A1*28 and ABCG2 c.421C[A polymorphisms in irinotecan-induced neutropenia in Asian cancer patients. Cancer Sci. 2007;98:1461-7.
22. Okuyama Y, Hazama S, Nozawa H, et al. Prospective phase II study of FOLFIRI for mCRC in Japan, including the analysis of UGT1A1 28/6 polymorphisms. Jpn J Clin Oncol. 2011;41: 477-82.
23. Han JY, Lim HS, Shin ES, et al. Influence of the organic aniontransporting polypeptide 1B1 (OATP1B1) polymorphisms on irinotecan-pharmacokinetics and clinical outcome of patients with advanced non-small cell lung cancer. Lung Cancer. 2008;59:69-75.
24. Hoskins JM, Goldberg RM, Qu P, et al. UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters. J Natl Cancer Inst. 2007;99:1290-5.
25. Stewart CF, Panetta JC, O'Shaughnessy MA, et al. UGT1A1 promoter genotype correlates with SN-38 pharmacokinetics, but not severe toxicity in patients receiving low-dose irinotecan. J Clin Oncol. 2007;25:2594-600.
26. Marcuello E, Páez D, Paré L, et al. A genotype-directed phase I-IV dose-finding study of irinotecan in combination with fluorouracil/leucovorin as first-line treatment in advanced colorectal cancer. Br J Cancer. 2011;105:53-7.
27. Satoh T, Ura T, Yamada Y, et al. Genotype-directed, dose-finding study of irinotecan in cancer patients with UGT1A1*28 and/or UGT1A1*6 polymorphisms. Cancer Sci. 2011;102:1868-73.
28. Toffoli G, Cecchin E, Corona G, et al. The role of UGT1A1*28 polymorphism in the pharmacodynamics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer. J Clin Oncol. 2006;24:3061-8.
29. Cortejoso L, García MI, García-Alfonso P, et al. Differential toxicity biomarkers for irinotecan- and oxaliplatin-containing chemotherapy in colorectal cancer. Cancer Chemother Pharmacol. 2013. doi:10.1007/s00280-013-2145-6.